[시장보고서]간세포 성장인자(HGFs) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

간세포 성장인자(HGFs) 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Hepatocyte Growth Factors (HGFs) Market (Type: Phase III [Ongoing], Phase II [Approved], Phase II [Ongoing], Phase I, and Preclinical) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1531041

리서치사 : Transparency Market Research

발행일 : 2024년 06월

페이지 정보 : 영문 141 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,372,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,707,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,041,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

간세포 성장인자(HGFs) 시장 - 조사 범위

TMR의 조사 보고서 "간세포 성장인자(HGFs) 세계 시장"은 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하고 있습니다. 이 보고서는 2024년을 기준 연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지의 세계 간세포 성장인자(HGFs) 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 간세포 성장인자(HGFs) 시장의 연평균 복합 성장률(CAGR %)도 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 간세포 성장인자(HGFs) 시장을 추론했습니다.

시장 스냅샷
2023년 시장 규모	7,030만 달러
2034년 시장 규모	1억 4,100만 달러
CAGR	6.5%

이 보고서는 세계 간세포 성장인자(HGFs) 시장의 경쟁 환경을 조사하고 있습니다. 세계 간세포 성장인자(HGFs) 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성으로 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등은 세계 간세포 성장인자(HGFs) 시장 기업의 속성 중 일부로 이 보고서에서 다루고 있습니다.

시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
- ViroMed
- AnGes, Inc.
- M3 Biotechnology, Inc.
- AVEO Pharmaceuticals, Inc.
- Molecular Partners AG
- YooYoung Pharmaceutical Co., Ltd.
- F-star Therapeutics Inc.
- Galaxy Bio Tech
- Kringle Pharma

ksm

영문 목차

영문목차

Hepatocyte Growth Factors (HGFs) Market - Scope of Report

TMR's report on the global hepatocyte growth factors (HGFs) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global hepatocyte growth factors (HGFs) market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hepatocyte growth factors (HGFs) market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the hepatocyte growth factors (HGFs) market.

Market Snapshot
Market Value in 2023	US$ 70.3 Mn
Market Value in 2034	US$ 141 Mn
CAGR	6.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hepatocyte growth factors (HGFs) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hepatocyte growth factors (HGFs) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hepatocyte growth factors (HGFs) market.

The report delves into the competitive landscape of the global hepatocyte growth factors (HGFs) market. Key players operating in the global hepatocyte growth factors (HGFs) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hepatocyte growth factors (HGFs) market profiled in this report.

Key Questions Answered in Global hepatocyte growth factors (HGFs) Market Report:

What is the sales/revenue generated by hepatocyte growth factors (HGFs) across all regions during the forecast period?
What are the opportunities in the global hepatocyte growth factors (HGFs) market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Hepatocyte Growth Factors (HGFs) Market - Research Objectives and Research Approach

The comprehensive report on the global hepatocyte growth factors (HGFs) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hepatocyte growth factors (HGFs) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hepatocyte growth factors (HGFs) market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Hepatocyte Growth Factors (HGFs) Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, 2020-2034

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Type

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2020-2034
- 6.3.1. Phase III (Ongoing)
- 6.3.2. Phase II (Approved)
- 6.3.3. Phase II (Ongoing)
- 6.3.4. Phase I
- 6.3.5. Preclinical
6.4. Market Attractiveness Analysis, by Type

7. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Application

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2020-2034
- 7.3.1. Oncology
- 7.3.2. Cardiovascular
- 7.3.3. Central Nervous System
- 7.3.4. Hematological Disorders
7.4. Market Attractiveness Analysis, by Application

8. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by End-user

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
- 8.3.1. Pharmaceutical and Biotechnology Companies
- 8.3.2. CMOs and CDMOs
- 8.3.3. Research Centers & Academic Institutes
8.4. Market Attractiveness Analysis, by End-user

9. Global Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2020-2034
- 10.3.1. Phase III (Ongoing)
- 10.3.2. Phase II (Approved)
- 10.3.3. Phase II (Ongoing)
- 10.3.4. Phase I
- 10.3.5. Preclinical
10.4. Market Value Forecast, by Application, 2020-2034
- 10.4.1. Oncology
- 10.4.2. Cardiovascular
- 10.4.3. Central Nervous System
- 10.4.4. Hematological Disorders
10.5. Market Value Forecast, by End-user, 2020-2034
- 10.5.1. Pharmaceutical and Biotechnology Companies
- 10.5.2. CMOs and CDMOs
- 10.5.3. Research Centers & Academic Institutes
10.6. Market Value Forecast, by Country, 2020-2034
- 10.6.1. U.S.
- 10.6.2. Canada
10.7. Market Attractiveness Analysis
- 10.7.1. By Type
- 10.7.2. By Application
- 10.7.3. By End-user
- 10.7.4. By Country

11. Europe Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2020-2034
- 11.3.1. Phase III (Ongoing)
- 11.3.2. Phase II (Approved)
- 11.3.3. Phase II (Ongoing)
- 11.3.4. Phase I
- 11.3.5. Preclinical
11.4. Market Value Forecast, by Application, 2020-2034
- 11.4.1. Oncology
- 11.4.2. Cardiovascular
- 11.4.3. Central Nervous System
- 11.4.4. Hematological Disorders
11.5. Market Value Forecast, by End-user, 2020-2034
- 11.5.1. Pharmaceutical and Biotechnology Companies
- 11.5.2. CMOs and CDMOs
- 11.5.3. Research Centers & Academic Institutes
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
- 11.7.1. By Type
- 11.7.2. By Application
- 11.7.3. By End-user
- 11.7.4. By Country/Sub-region

12. Asia Pacific Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2020-2034
- 12.3.1. Phase III (Ongoing)
- 12.3.2. Phase II (Approved)
- 12.3.3. Phase II (Ongoing)
- 12.3.4. Phase I
- 12.3.5. Preclinical
12.4. Market Value Forecast, by Application, 2020-2034
- 12.4.1. Oncology
- 12.4.2. Cardiovascular
- 12.4.3. Central Nervous System
- 12.4.4. Hematological Disorders
12.5. Market Value Forecast, by End-user, 2020-2034
- 12.5.1. Pharmaceutical and Biotechnology Companies
- 12.5.2. CMOs and CDMOs
- 12.5.3. Research Centers & Academic Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
- 12.7.1. By Type
- 12.7.2. By Application
- 12.7.3. By End-user
- 12.7.4. By Country/Sub-region

13. Latin America Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2020-2034
- 13.3.1. Phase III (Ongoing)
- 13.3.2. Phase II (Approved)
- 13.3.3. Phase II (Ongoing)
- 13.3.4. Phase I
- 13.3.5. Preclinical
13.4. Market Value Forecast, by Application, 2020-2034
- 13.4.1. Oncology
- 13.4.2. Cardiovascular
- 13.4.3. Central Nervous System
- 13.4.4. Hematological Disorders
13.5. Market Value Forecast, by End-user, 2020-2034
- 13.5.1. Pharmaceutical and Biotechnology Companies
- 13.5.2. CMOs and CDMOs
- 13.5.3. Research Centers & Academic Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
- 13.7.1. By Type
- 13.7.2. By Application
- 13.7.3. By End-user
- 13.7.4. By Country/Sub-region

14. Middle East & Africa Hepatocyte Growth Factors (HGFs) Market Analysis and Forecast

14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2020-2034
- 14.3.1. Phase III (Ongoing)
- 14.3.2. Phase II (Approved)
- 14.3.3. Phase II (Ongoing)
- 14.3.4. Phase I
- 14.3.5. Preclinical
14.4. Market Value Forecast, by Application, 2020-2034
- 14.4.1. Oncology
- 14.4.2. Cardiovascular
- 14.4.3. Central Nervous System
- 14.4.4. Hematological Disorders
14.5. Market Value Forecast, by End-user, 2020-2034
- 14.5.1. Pharmaceutical and Biotechnology Companies
- 14.5.2. CMOs and CDMOs
- 14.5.3. Research Centers & Academic Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
- 14.7.1. By Type
- 14.7.2. By Application
- 14.7.3. By End-user
- 14.7.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
- 15.3.1. ViroMed
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Financial Overview
  - 15.3.1.5. Strategic Overview
- 15.3.2. AnGes, Inc.
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Financial Overview
  - 15.3.2.5. Strategic Overview
- 15.3.3. M3 Biotechnology, Inc.
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Financial Overview
  - 15.3.3.5. Strategic Overview
- 15.3.4. AVEO Pharmaceuticals, Inc.
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Financial Overview
  - 15.3.4.5. Strategic Overview
- 15.3.5. Molecular Partners AG
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Financial Overview
  - 15.3.5.5. Strategic Overview
- 15.3.6. YooYoung Pharmaceutical Co., Ltd.
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Financial Overview
  - 15.3.6.5. Strategic Overview
- 15.3.7. F-star Therapeutics Inc.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Financial Overview
  - 15.3.7.5. Strategic Overview
- 15.3.8. Galaxy Bio Tech
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Financial Overview
  - 15.3.8.5. Strategic Overview
- 15.3.9. Kringle Pharma
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Financial Overview
  - 15.3.9.5. Strategic Overview

한글목차

간세포 성장인자(HGFs) 시장 - 조사 범위

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계의 시장 분석과 예측 : 유형별

제7장 세계의 시장 분석과 예측 : 용도별

제8장 세계의 시장 분석과 예측 : 최종사용자별

제9장 세계의 시장 분석과 예측 : 지역별

제10장 북미의 시장 분석과 예측

제11장 유럽의 시장 분석과 예측

제12장 아시아태평양의 시장 분석과 예측

제13장 라틴아메리카의 시장 분석과 예측

제14장 중동 및 아프리카의 시장 분석과 예측

제15장 경쟁 상황